Novelix Pharmaceuticals Ltd

Lease details

• Lease executed on 19 Aug 2026 with Mr. Gnana Prakash Gattu.
• Land area: 37 Guntas (~0.925 acres) at Survey No. 917/6A, Markook, Telangana.
• Purpose: establish micro algae cultivation facilities and glass reactor installations.
• Term: 5-year lease starting 19 Aug 2026.
• Rent: Rs 5,000 monthly plus taxes; escalates 5% every three years.
• Lessor is promoter group, a non-exec director; transaction at arm's length.
• Lease is for domestic land use; location specified in filing.
• Annexure I provides regulatory disclosure per SEBI Listing Regulations.
• Related-party exposure disclosed; governance and arm's length terms maintained.
• Benefit: enables development of micro algae cultivation facilities.

Deviation & variation details

• Purpose: Deviation and Variation statement for quarter ended 30 June 2026.
• Audit Committee and Board reviewed on 13 August 2026.
• Original object: long-term funding including working capital and general corporate purposes.
• Original allocation: Rs 421.50 Lakhs; funds utilised: Rs 421.50 Lakhs.
• Modified object: not disclosed.
• Deviation/variation: amount not disclosed.
• Audit comments: No Comments.
• Monitoring agency: not disclosed.

Financial highlights

• Total revenue for quarter ended 30 Jun 2026: Rs 3,691.51 lakh.
• Profit after tax for quarter ended 30 Jun 2026: Rs 117.89 lakh.
• EPS (Basic/Diluted): Rs 0.49 per share (face value Rs 10).
• Single segment: Manufacturing and trading of active pharmaceutical ingredients.
• Total expenses for quarter: Rs 3,579.98 lakh.
• Board approved unaudited standalone results; limited review by CVS Balachandra Rao & Co.
• Quarter ended 30 Jun 2026; board approval date 13 Aug 2026.
• Paid up equity share capital: Rs 2,389.50 lakh.

Financial results and approvals

• Standalone unaudited quarterly results for quarter ended 30 June 2026 approved by the Board.
• Revenue from operations: ₹3,691.39 lakh; total revenue: ₹3,691.51 lakh.
• Net profit after tax: ₹117.89 lakh; basic EPS: ₹0.49.
• Limited Review Report indicates no material misstatement.
• Company operates a single segment: manufacturing and trading of active pharmaceutical ingredients.
• Board approval of results communicated in meeting held on 13 August 2026.

Meeting Details

• Board meeting on 13 August 2026 at the registered office; time not disclosed.

Key Agenda Items

• Consider and approve unaudited standalone results for quarter ended June 30, 2026, with limited review report.
• Any other matter with chair's permission.

Other Notes

• Trading window closed from 01-Jul-2026 until 48 hours after the meeting.

Dematerialisation status

• No dematerialisation/rematerialisation requests were received for the quarter; none were processed.

Key details

• Target Company: Novelix Pharmaceuticals Limited.
• Disclosing Party: Gattu Gnana Prakash; Arati Gattu; Neha Gattu (Promoter Group).
• Transaction Type: Acquisition of 600,000 voting shares via warrant conversion (preferential allotment).
• Pre-Transaction Holding: Gattu 399,047 shares (1.67%); Arati 100,000 (0.42%); Neha 100,000 (0.42%).
• Encumbrances: NIL for all three acquirers.
• Transaction Details: Shares acquired 400,000; 100,000; 100,000 respectively; date 9 July 2026.
• Post-Transaction Holding: 400,000; 100,000; 100,000 shares respectively (1.40%, 0.35%, 0.35%).
• Share Capital Context: Pre: Rs 238.95m; Post: Rs 284.70m; Pre-diluted Rs 272.70m; Post-diluted Rs 284.70m with 28.47m shares.

Key details

• Target Company: Novelix Pharmaceuticals Limited.
• Disclosing Party: Gattu Gnana Prakash; Arati Gattu; Neha Gattu (Promoter Group).
• Transaction Type: Acquisition of 100,000 equity shares each via warrant conversion under preferential allotment.
• Pre-Transaction Holding: 100,000 shares per acquirer; 0.42% voting rights; encumbrances NIL.
• Transaction Details: 100,000 shares per acquirer; date 09 July 2026; instrument: equity via warrants.
• Post-Transaction Holding: 400,000; 100,000; 100,000 shares; 1.40%, 0.35%, 0.35%.
• Date of Transaction: 09 July 2026.
• Before: equity capital Rs 238,950,000 (23,895,000 shares); diluted Rs 272,700,000.
• After: equity capital Rs 284,700,000 (28,470,000 shares); diluted Rs 284,700,000.
• Promoter Status: All acquirers belong to Promoter Group.